| Entry |
|
|---|
| Name |
Nesiritide (USAN/INN);
Natrecor (TN) |
|---|
| Formula |
C143H244N50O42S4
|
|---|
| Exact mass |
3461.7377
|
|---|
| Mol weight |
3464.0373
|
|---|
| Sequence |
Ser Pro Lys Met Val Gln Gly Ser Gly Cys Phe Gly Arg Lys Met Asp
Arg Ile Ser Ser Ser Ser Gly Leu Gly Cys Lys Val Leu Arg Arg His
(Disulfide bridge: 10-26) |
|---|
| Type |
Peptide |
|---|
| Remark |
|
|---|
| Efficacy |
Vasodilator, Atrial natriuretic peptide receptor agonist |
|---|
| Comment |
Recombinant of human B-type natriuretic peptide (BNP) [HSA: 4879]
Renin-angiotensin system antagonist
Treatment of congestive heart failure
|
|---|
| Target |
|
|---|
| Pathway |
| hsa04270 | Vascular smooth muscle contraction |
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
C CARDIOVASCULAR SYSTEM
C01 CARDIAC THERAPY
C01D VASODILATORS USED IN CARDIAC DISEASES
C01DX Other vasodilators used in cardiac diseases
C01DX19 Nesiritide
D05147 Nesiritide (USAN/INN)
Target-based classification of drugs [BR:br08310]
Enzymes
Lyases (EC4)
Phosphorus-oxygen lyases
NPR1
D05147 Nesiritide (USAN/INN)
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D05147
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D05147
|
|---|
| Other DBs |
|
|---|
| LinkDB |
|
|---|
